Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 20 August 2009, doi:10.1136/bmj.b2949
Cite this as: BMJ 2009;339:b2949
Andrew Connor, specialist registrar in renal and general medicine 1, Charlie Tomson, consultant nephrologist2
1 Department of Renal Medicine, Dorset County Hospital, Dorchester DT1 2JY, 2 Richard Bright Renal Unit, Southmead Hospital, Bristol BS10 5NB
Correspondence to: A Connor, 3 Hope Terrace, Martinstown DT2 9JN andrewconnor1974@hotmail.co.uk
| The first 150 words of the full text of this article appear below. |
Most patients with early chronic kidney disease are managed in primary care. These patients have an increased risk of cardiovascular disease; the lower the estimated glomerular filtration rate, the higher the risk.1 Patients with stages 1 to 4 of chronic kidney disease are more likely to die from cardiovascular disease than to require renal replacement therapy, and cardiovascular disease is the most common cause of death among dialysis and transplant patients.2
However, the causal pathway is unclear; conventional cardiovascular risk factors (including dyslipidaemia) may also cause kidney disease progression, but kidney disease may also cause cardiovascular disease through pathways unrelated to dyslipidaemia. The benefits of lipid lowering treatment in primary and secondary prevention of cardiovascular disease in people with preserved renal function are well established.3 4 Recent guidance from the National Institute for Health and Clinical Excellence (NICE) recommends treatment with statins for secondary prevention of cardiovascular disease in all patients
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses